ARTICLES BY SUZANNE HODSDEN

  •  “Smart” Contact Lens Uses Optical Biosensing To Detect Glucose
    “Smart” Contact Lens Uses Optical Biosensing To Detect Glucose

    Scientists at the University of Houston (UH) have developed a new approach to glucose-sensing contact lenses by integrating an optical sensor. Though the correlation between glucose levels in tear samples and traditional blood samples is not yet established, the researchers said that their “smart” contact lens prototype demonstrates the versatility of their biosensing technology and a possible non-invasive alternative to existing glucose monitors.

  • FDA Clears Abbott's Needle-Free CGM For Professional Use
    FDA Clears Abbott's Needle-Free CGM For Professional Use

    FDA has approved Abbott’s Freestyle Libre Pro System for professional continuous glucose monitoring (CGM), which provides clinicians with 14 days’ worth of patient data so they can make more informed clinical decisions regarding diabetes management. 

  • Boston Scientific Buys EndoChoice for $210M, Expands GI Business
    Boston Scientific Buys EndoChoice for $210M, Expands GI Business

    Boston Scientific has announced a $210 million deal to acquire EndoChoice Holdings, an Atlanta-based medtech specializing in endoscopic imaging systems, single-use devices, and infection control products. 

  • BrainScope’s Hand-Held Device Diagnoses “Full Spectrum” Of TBI, Headed To U.S. Market
    BrainScope’s Hand-Held Device Diagnoses “Full Spectrum” Of TBI, Headed To U.S. Market

    BrainScope — a medtech specializing in traumatic brain injury (TBI) diagnostic technology that is backed by the U.S. Department of Defense (DOD)— has announced FDA clearance for Ahead 300, a hand-held medical device capable of objectively assessing the likelihood of TBI. 

  • NIH-Funded Closed-Loop Device Controls Blood Pressure In Emergencies
    NIH-Funded Closed-Loop Device Controls Blood Pressure In Emergencies

    Scientists from the University of Texas in Arlington (UTA) have received a $440,670 National Institute of Health (NIH) grant for the continued development of a “closed-loop” blood pressure neurostimulation device for the cardiac care environment.  

  • NIH Awards $2.3M To Fund Study Of Pancreatic Cancer-Fighting Implant
    NIH Awards $2.3M To Fund Study Of Pancreatic Cancer-Fighting Implant

    The National Institute of Health has awarded a $2.3 million grant to CivaTech, developer of an implantable device that provides targeted radiation treatment for cancer patients.  CivaTech plans to use the grant to fund a clinical study that will evaluate safety and efficacy of the CivaSheet device in patients with pancreatic cancer.

  • FDA Draft Guidance Addresses Coordinated Development Of AST Devices, Antimicrobial Drugs
    FDA Draft Guidance Addresses Coordinated Development Of AST Devices, Antimicrobial Drugs

    FDA has published a draft guidance for industry outlining the agency’s approach to the coordinated development of antimicrobial drugs and antimicrobial susceptibility test (AST) devices. Though the agency wishes to better facilitate interactions between drug sponsors and device developers, FDA emphasized that applications will remain separate, and review timelines for separate products will not be influenced by each other.

  • J&J’s Acclarent Wins FDA Nod For Eustachian Tube Balloon Dilation System
    J&J’s Acclarent Wins FDA Nod For Eustachian Tube Balloon Dilation System

    Johnson & Johnson (J&J) subsidiary Acclarent announced that the FDA has awarded de novo approval to its balloon dilation system, the Aera System, which joins J&J’s portfolio of minimally invasive therapies for ear, nose, and throat (ENT) conditions. Aera is indicated for the treatment of persistent eustachian tube dysfunction (ETD).

  • J&J Buys Abbott’s Eye Unit for $4.3B - Abbott Turns Focus To Cardiovascular, Diagnostics
    J&J Buys Abbott’s Eye Unit for $4.3B - Abbott Turns Focus To Cardiovascular, Diagnostics

    Abbott has announced the sale of its medical optics business to Johnson & Johnson (J&J) in a deal worth $4.3 billion. Abbott continues to prepare for its acquisition of St. Jude later this year, and senior executives commented that the company is focused on building leadership positions in the cardiovascular device and diagnostic spaces.

  • Implanted Device Improves Breast Cancer Survival Rates In Mice, Study Shows
    Implanted Device Improves Breast Cancer Survival Rates In Mice, Study Shows

    Scientists from the University of Michigan (UM) have developed an implant that may one day act as an early warning system for metastatic tumors in lungs, liver, and brain caused by the spread of breast cancer. 

More Articles by Suzanne Hodsden

Suzanne Hodsden

Suzanne Hodsden is a contributor who writes regular life sciences news features for several publications. She holds degrees from Denison University and Bowling Green State University.